Sonoma Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of Microcyn® Technology, a proprietary and clinically proven platform for advanced wound care and antimicrobial applications. Established in 1999 as Micromed Laboratories Inc. in Petaluma, CA, the company has grown into a global leader in hypochlorous acid (HOCl) technology.

With a state-of-the-art manufacturing facility in Guadalajara, Mexico (certified under ISO:13485, ISO:9001, and FDA QSR), Sonoma Pharmaceuticals has successfully expanded its operations to over 50 countries. The company holds 53 U.S. and international patents and more than 40 regulatory clearances and approvals, underscoring its commitment to innovation and compliance with global healthcare standards.

Technology & Mechanism of Action:

Microcyn® Technology is a groundbreaking hypochlorous acid (HOCl)-based therapeutic solution designed to enhance healing, reduce infection risk, and mitigate inflammation through a biologically harmonious mechanism. Unlike conventional disinfectants, Microcyn® functions as a treatment modality that leverages the body’s innate immune response to accelerate tissue repair.

Key Mechanisms of Action:

• Antimicrobial Activity
  • Rapidly reduces microbial load and prevents infection.
  • Disrupts microbial cell walls through osmotic pressure, leading to cell lysis.
  • Proven efficacy against bacteria, viruses, fungi, and biofilms within 30 seconds in vitro.

• Anti-Inflammatory Effects

• Inhibits histamine release by 86%, reducing excessive inflammatory responses.

• Regenerative Properties

• Enhances capillary perfusion, boosting oxygen and nutrient delivery.
• Stimulates fibroblast migration and proliferation, accelerating granulation and epithelialization.
• Promotes optimal wound closure with minimal scar formation.

Clinical Applications & Safety Profile:

Microcyn® Technology is utilized across a broad spectrum of medical and healthcare applications, including:

• Advanced Wound Care (acute and chronic wounds, burns, post-surgical wounds)
• Dermatology (atopic dermatitis, eczema, acne, post-laser treatment)
• Ophthalmology (eyelid disinfection, ocular wound healing)
• Dentistry & Oral Care (periodontitis, root canal treatment, oral irrigation)
• Respiratory & ENT Applications (nasal irrigation, sinus infections)
• Urology (urinary tract infections)
• First Aid & Surface Disinfection (hospital and environmental hygiene)

Safety & Compatibility:

• Non-toxic, non-cytotoxic, and non-irritating
• Safe for skin, mucous membranes, cartilage, bone, soft and nerve tissues
• No systemic absorption or accumulation of toxic ingredients
• Suitable for all age groups, including pediatric and geriatric patients
• Can be used as a monotherapy or as part of a comprehensive treatment regimen

Market Positioning & Competitive Advantages:

• Since 2001, Microcyn® has remained at the forefront of hypochlorous acid (HOCl)-based wound care.
• As the first stable HOCl formulation introduced in Europe and the U.S., Microcyn® continues to set industry benchmarks for efficacy, safety, and clinical validation.

Key Differentiators:

• Proprietary, evidence-based, and patented technology
• Clinically proven to accelerate healing by 33%
• Reduced reliance on antibiotics and steroids
• Enhanced patient outcomes with minimal adverse effects
• Environmentally friendly formulation with rapid odor reduction

Conclusion:

Microcyn® Technology represents a groundbreaking innovation in wound healing and antimicrobial therapy. Its ability to enhance tissue regeneration, minimize infection risk, and reduce inflammation while maintaining an exceptional safety profile makes it an vital component in modern medical and healthcare settings.

With over two decades of clinical success, Microcyn® continues to lead the market, providing cutting-edge, patient-centric solutions that drive improved healthcare outcomes worldwide.